Agilent Shares Drop 10 Percent After Quarterly Report; Bruker Rises
Agilent Technologies’ share price fell 10 percent for the five-day period ending Tuesday after the company reported its quarterly financials on Thursday.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.